MatthewRionZibelmanMD

Oncology • Philadelphia, PA

Genitourinary Oncology

Physician

Join to view full profile

Dr. Zibelman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zibelman's full profile

Already have an account?

Office
333 Cottman Ave
Philadelphia, PA 19111
Phone+1 215-728-2500

Fax+1 215-728-3639

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2007 - 2011
Lewis Katz School of Medicine at Temple UniversityClass of 2007

Certifications & Licensure

PA State Medical License 2012 - 2024
IL State Medical License 2007 - 2014
WI State Medical License 2011 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma Start of enrollment: 2017 Jun 12
Active, not recruiting
Phase 1, Phase 2
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma Start of enrollment: 2017 Nov 27
Recruiting
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer Start of enrollment: 2021 Nov 05
Suspended
Phase 1
Roles: Contact
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma Start of enrollment: 2022 Jan 21
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer Start of enrollment: 2023 Jan 30
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
Daniel M Geynisman, Philip H Abbosh, Eric Ross, Matthew R Zibelman, Pooja Ghatalia
Journal of Clinical Oncology. 2024-12-16
Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles.
Anumita Chakraborty, Jill Hasler, Elizabeth Handorf, Fern Anari, Pooja Ghatalia
Clinical Genitourinary Cancer. 2024-12-01
1 citations
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S...
Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis
European Urology Oncology. 2024-10-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member